Strategy Consulting

Innovation in life sciences has reached unprecedented levels of complexity and risk. Advances in basic science, genetics, proteomics, and translational sciences have led to a proliferation of drug targets and candidates. Increasingly tailored for specific and narrower populations, these drugs challenge our existing economic and executional models for drug development and commercialization.

In parallel, health systems are struggling to absorb and pay for the cost of innovation as overall system costs rise due to aging populations, inflation, and increasingly challenging health needs that frequently require multi-modal approaches to treatment. Public and private payors continue to overhaul business models to respond and survive in this new environment. Patients, similarly, are being asked to bear a greater proportion of their healthcare costs, and as a result have become far more active and discerning consumers of the healthcare system.

Lumanity’s strategy capability blends essential cross-functional scientific, clinical, regulatory, and commercial perspectives to help our clients navigate the web of complex decisions and position their assets and organizations for success.

In the biopharma sector, expert advice is vital for shaping decisions in scientific innovation. Innovation of itself is not enough to drive value. Strategic planning is crucial to mitigate risks and demonstrate investment potential to stakeholders. Our biotech and innovation experts can help you build a sustainable growth strategy, elucidate your value proposition and competitive differentiation, and strengthen your valuation and communicate to investors and potential partners.